Jonathan Lee, MD, MSc

Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.

Experts discuss the importance of molecular profiling and testing in managing metastatic pancreatic cancer, highlighting advancements in treatment options.

Innovative drug development for pancreatic cancer focuses on KRAS and PRMT5 inhibitors, exploring combinations with chemotherapy for enhanced treatment efficacy.

Experts discuss the impact of NCCN guidelines on pancreatic cancer treatment, highlighting new therapies and future advancements in patient care.

Experts discuss the importance of communication and patient support in managing pancreatic cancer treatment and aligning care goals with patient needs.

Experts emphasize the importance of communication and patient support in managing pancreatic cancer, focusing on aligning treatment goals with personal preferences.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Clinicians discuss managing diarrhea and nutritional support for pancreatic cancer patients, emphasizing the importance of a comprehensive care team.

Discover how NALIRIFOX offers a promising alternative to FOLFIRINOX, enhancing treatment options and reducing toxicities for pancreatic cancer patients.

Healthcare professionals discuss effective strategies for dose reduction in cancer treatment, emphasizing patient reassurance and maintaining treatment efficacy.

Explore strategies for adjusting chemotherapy dosages based on genetic mutations, enhancing patient safety and treatment efficacy in clinical practice.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.

Jonathan Lee, MD, MSc, offers his tips for interviewing for a hematology/oncology fellowship.

Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.

Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

The chief oncology/hematology fellow at Weill Cornell Medicine details everything that he wishes he had known entering his first year of fellowship.